GSK (GSK) said Tuesday that regulators in Europe, Japan and China have accepted separate applications to review its depemokimab drug candidate for a pair of asthma indications, including as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.
The company said it is also seeking approval to market the monoclonal antibody as a maintenance add-on therapy for type 2 inflammation with an eosinophilic phenotype in patients aged 12 and up whose asthma is inadequately controlled by corticosteroids.
GSK said that if approved, depemokimab will be the first ultra-long-acting biologic with six-month dosing and that it is not currently approved in any jurisdiction.
Price: 35.53, Change: +0.03, Percent Change: +0.08
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。